Status:
COMPLETED
Anastrozole and Letrozole
Lead Sponsor:
UConn Health
Collaborating Sponsors:
Connecticut Breast Health Initiative
Conditions:
Breast Cancer
Eligibility:
FEMALE
40+ years
Brief Summary
Aromatase Inhibitors (AI) are effective for secondary prevention of breast cancer and may soon replace tamoxifen as first-line therapy in the treatment of hormone-sensitive breast cancer. However, bec...
Eligibility Criteria
Inclusion
- Postmenopausal women with diagnosis of breast cancer - have not started Arimidex or Femara yet, but will be starting .
Exclusion
- History of metastasis
- History of chronic kidney
- Liver GI disease
- Disorders affecting calcium metabolism
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00762294
Start Date
May 1 2007
End Date
December 1 2011
Last Update
December 15 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Connecticut HEalth Center
Farmington, Connecticut, United States, 06030